RSV-F Protein (Native, RSV)

1.Immobilized Human respiratory syncytial virus (RSV) (A2) Prefusion glycoprotein F/ RSV-preF Protein (Cat:11049-VNAS) at 0.5μg/mL (100μL/well) can bind RSV specific antibody which targets antigenic site II (Palivizumab), the EC50 is 0.5 ng/mL-1.7 ng/mL. 2.Immobilized Human respiratory syncytial virus (RSV) (A2) Prefusion glycoprotein F/ RSV-preF Protein (Cat:11049-VNAS) at 0.5μg/mL (100μL/well) can bind RSV specific antibody which targets antigenic Site Ø (Nirsevimab), the EC50 is 0.45 ng/mL-1.35 ng/mL (Routinely tested) . 3.Immobilized Human respiratory syncytial virus (RSV) (A2) Prefusion glycoprotein F/ RSV-preF Protein (Cat:11049-VNAS) at 0.5μg/mL (100μL/well) can bind prefusion specific antibody which targets antigenic Site V (Suptavumab), the EC50 is 0.05 ng/mL-0.15 ng/mL (Routinely tested) . 4.Nirsevimab-derived anti-RSV-preF antibody, Human IgG1 captured on Protein A chip, can bind Human respiratory syncytial virus (RSV) (A2) Prefusion glycoprotein F/ RSV-preF Protein (Cat. No. 11049-VNAS) with an affinity constant of 6.290 nM as determined in an SPR assay (Biacore 8K) (Routinely tested) .

The recombinant RSV (A2) Prefusion glycoprotein F has a predicted molecular mass of 54.5 kDa.It migrates as an approximately 57.6 kDa band in SDS-PAGE under reducing conditions. The molecular weight of this protein is around 160 kDa -190kDa verified by SEC-MALS.